Compare W W Grainger Inc (GWW) vs TG Therapeutics Inc (TGTX) Price & Performance

W.W. Grainger (GWW) trades at $1,304.88, up 0.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 results, beating EPS and revenue estimates, and raised its full-year outlook. Revenue grew to $18.8 billion in 2026, with a net income margin of 9.92%. Analyst consensus is a 'Hold' with a $1,320 price target, though institutional sentiment is mixed amid high valuation multiples.

GWW's earnings momentum and market share gains support upside potential, but elevated P/E of 33.19 and bearish technicals pose near-term risks. Investors should weigh robust fundamentals against valuation concerns and macroeconomic pressures affecting industrial demand.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.